The PDUFA date of November 27, 2026 is the next major binary catalyst. Watch for any FDA advisory committee meeting announcement and potential European regulatory engagement updates. The cardiac data strengthens the clinical profile but the approval decision remains the primary value driver.
Price Chart
Executive Summary
BridgeBio presented new exploratory cardiac data from the Phase 3 FORTIFY trial of BBP-418 in LGMD2I/R9 at the World Muscle Society congress. Key findings include 100% normalization of HS troponin I in treated patients with elevated baseline levels vs 40% on placebo (p=0.0248), and 54% stable/improved LVEF vs 25% on placebo (p=0.0262). BBP-418 is under FDA Priority Review with a PDUFA date of November 27, 2026, and the company plans to initiate pediatric studies in 2027.
Key Facts
- BBP-418 met all primary and secondary endpoints at the pre-specified 12-month interim analysis of FORTIFY
- 100% of BBP-418-treated participants with elevated HS troponin I at baseline returned to normal range by Month 12 vs 40% on placebo (p=0.0248)
- 54% of BBP-418-treated participants had stable or improved LVEF at Month 12 vs 25% on placebo (p=0.0262)
- BBP-418 increased mean glycosylated αDG to levels of asymptomatic heterozygous FKRP carriers by Month 3, sustained through Month 12
- PDUFA target action date: November 27, 2026; Priority Review granted
- BridgeBio plans to initiate clinical studies in patients <12 years old in first half of 2027 and in LGMD2M/R13 and LGMD2U/R20 in the near future
- Approximately 7,000 individuals in the U.S. and Europe live with LGMD2I/R9 and other addressable α-dystroglycanopathies
Financial Impact
Potential first approved therapy for any form of LGMD, addressing ~7,000 patients in U.S./Europe. No revenue estimates provided.
Risk Factors
- FDA may not approve BBP-418 on the anticipated timeline or at all
- Exploratory cardiac analyses are not alpha-controlled and based on small sample sizes
- Observed biomarker changes may not predict long-term clinical benefit or prevent disease progression
- Competing therapies could emerge for LGMD2I/R9
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3374437 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 27, 2026 today | SC 13G | $68.25 | awaiting T+20 | — | $69.37 (+1.64%) |
Oct 22, 2026 5d ago | Press Release | $68.12 | awaiting T+20 | — | $69.37 (+1.84%) |
Oct 13, 2026 14d ago | 8-K | $63.30 | awaiting T+20 | — | $69.37 (+9.59%) |
Oct 6, 2026 21d ago | Press Release | $66.96 | awaiting T+20 | — | $69.37 (+3.60%) |
Oct 5, 2026 22d ago | Press Release | $66.96 | awaiting T+20 | — | $69.37 (+3.60%) |
Oct 5, 2026 22d ago | Press Release | $66.14 | awaiting T+20 | — | $69.37 (+4.88%) |
Sep 18, 2026 5w ago | Press Release | $66.58 $67.94 | ▲ +2.04% | ▲ +2.95% | $69.37 (+4.19%) |
Aug 31, 2026 8w ago | 8-K | $76.59 $65.97 | ▼ −13.87% | ▼ −13.68% | $69.37 (−9.43%) |
Aug 26, 2026 8w ago | Press Release | $79.37 $66.28 | ▼ −16.49% | ▼ −16.72% | $69.37 (−12.60%) |
Aug 22, 2026 9w ago | Institutional Cluster | $81.07 $69.23 | ▼ −14.60% | ▼ −15.92% | $69.37 (−14.43%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers